A postdoc position is available in the laboratory of Yonghao Yu, in the Department of Biochemistry of UT Southwestern Medical Center. By utilizing integrative mass spectrometry-based proteomic, and more traditional biochemical/molecular biochemical approaches, the focuses of our group are to decipher the fundamental mechanisms of covalent protein modifications in various diseases, including cancer, metabolic syndrome and neurodegenerative diseases. We are also using the chemoproteomic platform to discover novel small molecule inhibitors towards the “undruggable proteome”. The Yu lab is actively collaborating with a number of biotech/pharma companies.
On the proteomic side, we are particularly interested in developing next generation large-scale quantitative mass spec technologies, including those relevant to sample preparation, instrumentation and computation. We then use these methods to characterize covalent protein modifications (e.g., phosphorylation and ADP-ribosylation, etc). Several representative recent publications include:
(1) Kim et al., eLife, 9, e60637, (2020).
(2) Wang et al., Nature Chemical Biology, 15, 1223, (2019)
(3) Zhang, et al., Nature Methods, 10(10):981-4 (2013).
On the cancer biology side, our group aims to translate the discoveries made by the large scale proteomic experiments to understand the role of cell-autonomous regulation of oncogenesis. We are particularly interested in the role of PARP and Poly-ADP-ribosylation signaling in mediating cellular DNA damage response. We are also interested in the role of mTOR and phosphorylation signaling in mediating cell growth and cell metabolism. A distinct advantage of the Yu lab is a large proteomic database of the various PTMs, which serves as a highly unique resource for follow-up functional studies.
Several representative recent publications include:
(1) Wang et al., Nature Communications, 10, 3201 (2019).
(2) Ding et al., Nature Cell Biology, 18, 319-327 (2016).
(3) Li et al., Genes and Development, 29(2):157-70 (2015).
(4) Yu et al., Science, 332(6035), 1322-1326 (2011).
On the translational research side, the group aims at developing small molecule-based therapeutics for treating cancer. As an example, we recently developed the first PARP1 PROTAC compound (Wang et al., Nature Chemical Biology, 2019). In addition to the research projects within the group, our group is actively engaged in numerous collaborations with biotech/pharma. The interdisciplinary and collaborative environment of our group (i.e., proteomics, mechanistic biology and drug development) provides highly unique career development opportunities for the trainees.
Requirement: Candidates must hold a Ph.D. and/or M.D. degree. Experience in: i) biochemistry, ii) molecular biology and structural biology iii) mammalian cell biology, iv) cancer biology and metabolism v) Proteomics Leading to publication in peer-reviewed journals are recommended. Prior exposure to mass spectrometry is preferred, but NOT required.
Interested individuals should send a CV, statement of interests, and a list of three references to:
Yonghao Yu, Ph.D. Yonghao.
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9038
Information on our postdoctoral training program and benefits can be found in our Postdoc Handbook or at http://www.utsouthwestern.edu/postdocs.
UT Southwestern Medical Center is committed to an educational and working environment that provides equal opportunity to all members of the University community. In accordance with federal and state law, the University prohibits unlawful discrimination, including harassment, on the basis of: race; color; religion; national origin; sex; including sexual harassment; age; disability; genetic information; citizenship status; and protected veteran status. In addition, it is UT Southwestern policy to prohibit discrimination on the basis of sexual orientation, gender identity, or gender expression.